Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00552396 · ClinicalTrials.gov registry record · Phase 1
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
A Phase 1 study, sponsored by Innate Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00552396 is a Phase 1 study that has completed, run by Innate Pharma. The registered enrollment target is 32 participants.
The verdict
NCT00552396, a Phase 1 study, has completed, sponsored by Innate Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Development of new treatments for diseases such as multiple myeloma is a focus for research. The research being conducted is on treatment called Anti-KIR (1-7F9), which activates the body's own cells to kill tumor cells. This is different from many other treatments where chemicals are given to kill tumor cells. The purpose of the study is to determine a safe dose of Anti-KIR (1-7F9) to administer in humans and to gain information about its effectiveness in the treatment of multiple myeloma.
Interventions
- DRUG Anti-KIR (1-7F9)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00552396
The ClinicalTrials.gov registry entry for NCT00552396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-KIR (1-7F9) is the first listed.
NCT00552396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00552396 about?
NCT00552396 is a clinical study titled "An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma". Development of new treatments for diseases such as multiple myeloma is a focus for research. The research being conducted is on treatment called Anti-KIR (1-7F9), which activates the body's own cells to kill tumor cells. This is different from many other treatments where chemicals are given to kill ...
What is the current status of trial NCT00552396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2007-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00552396?
The interventions under investigation include: Anti-KIR (1-7F9) (DRUG).
Who is sponsoring clinical trial NCT00552396?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.